Visit Konga

Thursday, 10 December 2015

Controversial Pharmaceutical Executive Revealed as Buyer of $2M Wu-Tang Clan Album


A pharmaceutical executive who sparked international outrage when his firm raised the price of a drug used to treat AIDS patients to $750-per-pill was revealed Wednesday to have bought a single record by the hip-hop group Wu-Tang Clan for $2 million.

Bloomberg reported that Martin Shkreli, the CEO of Turing Pharmaceuticals, had purchased the only extant copy of the album "Once Upon A Time in Shaolin". The album, which was produced last year, includes 31 tracks and a leatherbound 174-page book filled with lyrics and background information on the songs.

When the auction was announced in March 2014, Wu-Tang Clan producer RZA described the album as "a piece of art like nobody else has done in the history of music. We're making a single-sale collector's item. This is like someone having the scepter of an Egyptian king."

In response to Bloomberg's report that Shkreli had bought the album, RZA issued a statement to the magazine that said, "The sale of Once Upon a Time in Shaolin was agreed upon in May, well before Martin Skhreli’s [sic] business practices came to light. We decided to give a significant portion of the proceeds to charity."


Shkreli caused an uproar in September after news broke that Turing increased by more than 5,000 percent the price of Daraprim, a drug used to treat a life-threatening infection, jacking it up from $13.50 to $750 per pill.

No comments:

Post a Comment